Consensus Discussion and Conclusions
A consensus view of the role of Sandostatin® in acromegaly and the indications for its use were formulated after discussion of the various papers and posters presented at the meeting. For this purpose the participants separated into three working parties which reviewed Sandostatin therapy in (I) newly diagnosed and previously untreated acromegalic patients, in (II) treatment of the perioperative period before pituitary surgery or in (III) previously treated acromegalic patients where surgery and/or radiotherapy had failed to control activity of the acromegalic process. The reports of the working parties were then presented at a gathering of all participants and recommendations made to guide those using the drug for the first time. The ensuing discussion also highlighted the many aspects requiring further assessment and the difficulty of conducting a “conventional” drug trial in patients with acromegaly.
KeywordsPlacebo Carbohydrate Adenoma Neuropathy Diarrhea
Unable to display preview. Download preview PDF.
- 2.Klijn JGM, Lamberts SWJ, de Jong FH, van Dongen KJ, Birkenhäger JC (1980) Interrelationships between tumour size, age,Consensus Discussion and Conclusionsplasma growth hormone and incidence of extrasellar extension in acromegalic patients. Acta Endocrinol 95: 289–297Google Scholar
- 7.Lamberts SWJ, Verleun T, Hofland LJ, Del Pozo E (1987) A comparison between the effects of Sandostatin (SMS 201–995), bromocriptine and a combination of both drugs on hormone release by the cultured pituitary tumour cells of acromegalic patients. Clin Endocrinol (Oxf) 27: 11–23CrossRefGoogle Scholar
- 10.Landolt AM, Keller PJ, Froesch ER, Müller J (1982) Bromocriptine: does it jeopardise the results of later surgery for prolactinomas? Lancet II: 657–658Google Scholar
- 12.Pieters GFFM, Smals AGH, Kloppenborg PWC (1986) Long-term treatment of acromegaly with the somatostatin analogue SMS 201–995. N Engl J Med 314: 1391 (letter)Google Scholar